低危和中危前列腺癌患者剂量递增立体定向体部放疗1期试验的结果
这项前瞻性1期剂量递增试验纳入26例低危和中危前列腺癌患者,分3组分别接受40 Gy、45 Gy、50 Gy(5次)照射。各剂量组均未出现3级及以上毒性,45 Gy和50 Gy组前列腺特异性抗原最低值显著低于40 Gy组(P<.05),40 Gy组出现2例生化失败。
要点
- 26例低危和中危前列腺癌患者接受40、45、50 Gy(5次)立体定向体部放疗,各组均未出现3级及以上毒性。
- 45 Gy和50 Gy组前列腺特异性抗原最低值显著低于40 Gy组(P<.05)。
- 40 Gy组出现2例生化失败,无生化失败生存率为92%,前列腺特异性抗原生存率为100%, actuarial总生存率为96%。
核心结论
- 这项前瞻性1期剂量递增研究显示,40 Gy、45 Gy、50 Gy各剂量水平的立体定向体部放疗具有可接受的泌尿生殖系统和胃肠道毒性。
- 尽管各组间生化失败无差异,但45 Gy和50 Gy较高剂量与前列腺特异性抗原最低值改善相关。
- 研究结果将用于开展更大规模的前瞻性研究以证实这些发现。
研究设计与样本
- 前瞻性1期剂量递增试验,经机构审查委员会批准,2011年至2016年纳入26例低危和中危前列腺癌患者。
- 患者分3组分别接受40 Gy(9例)、45 Gy(10例)、50 Gy(7例),均为5次照射至前列腺。
- 未接受雄激素剥夺治疗;采用扩展前列腺癌指数综合量表和美国泌尿协会问卷前瞻性测量自报生活质量,按常见不良事件评价标准(版本4.03)收集急性和晚期毒性,采用Phoenix定义计算结局。
主要发现
- 中位随访67.2个月(范围71-230个月),所有组扩展前列腺癌指数综合量表和美国泌尿协会评分先升高后于2年内恢复至基线。
- 无3级及以上毒性,各治疗组间毒性无显著差异。
- 45 Gy和50 Gy组前列腺特异性抗原最低值显著低于40 Gy组(P<.05);40 Gy、45 Gy、50 Gy组前列腺特异性抗原最低值分别为0.6、0.1、0.1 ng/mL。
- 40 Gy组在43个月和62个月观察到2例生化失败,无生化失败生存率为92%;前列腺特异性抗原生存率为100%, actuarial总生存率为96%。
关键数值与推荐
- 40 Gy组无生化失败生存率为92%,前列腺特异性抗原生存率为100%, actuarial总生存率为96%。
- 45 Gy和50 Gy组前列腺特异性抗原最低值显著低于40 Gy组(P<.05);40 Gy、45 Gy、50 Gy组前列腺特异性抗原最低值分别为0.6、0.1、0.1 ng/mL。
- 各剂量组均未出现3级及以上毒性,治疗组间毒性无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出研究结果将用于开展更大规模的前瞻性研究以证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study presents a prospective phase 1, institutional review board-approved dose-escalated stereotactic body radiation therapy trial for prostate cancer (CaP) to assess the impact of dose level on quality of life, toxicity, and clinical outcomes. METHODS AND MATERIALS: From 2011 to 2016, 26 patients with low- and intermediate-risk CaP received 40, 45, and 50 Gy in 5 fractions to the prostate in cohorts of 9, 10, and 7 patients. Self-reported quality of life was prospectively measured from the Expanded Prostate Cancer Index Composite and American Urological Association. Common Terminology Criteria for Adverse Events (version 4.03) data were collected to observe acute and late toxicities. The Phoenix definition was used to calculate outcome. No patients received androgen deprivation therapy. RESULTS: Median follow-up was 67.2 months (range, 71-230 months). There was an increase in Expanded Prostate Cancer Index Composite and American Urological Association scores followed by a return to baseline over 2 years for all cohorts. There were no grade 3 or higher toxicities or significant differences in toxicity between treatment arms. The prostate-specific antigen (PSA) nadir was significantly lower in the 45-Gy and 50-Gy cohorts when compared with the 40-Gy cohort (P < .05). Two biochemical failures were observed in the 40-Gy arm after 43 and 62 months, resulting in a freedom from biochemical failure rate of 92%. PSA survival was 100%, and actuarial overall survival was 96%. PSA nadir was 0.6, 0.1, and 0.1 ng/mL, in the 40-Gy, 45-Gy, and 50-Gy cohorts, respectively. CONCLUSIONS: This prospective, phase 1 dose-escalation study of stereotactic body radiation therapy for CaP identified acceptable genitourinary and gastrointestinal toxicity for each dose level of 40, 45, and 50 Gy. Although there was no difference in biochemical failure between the groups, we showed that higher doses of 45 and 50 Gy are associated with improved PSA nadir. The results of this study will be used to develop a larger prospective study to confirm the findings.
引用
- Potters L, Rana Z, Lee L, et al. Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 30721721. doi:10.1016/j.ijrobp.2019.01.092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。